The process
of determining the reimbursement of medicinal products in the Czech Republic is
complex and involves several key stakeholders who collectively influence the
final decision. In our recent post on decision-making practices, we highlighted
the role of health insurance companies in the reimbursement process. Now, let’s
take a closer look at the entities involved and how the entire mechanism works.
The process of determining the reimbursement of medicinal products in the Czech Republic is complex and involves several key stakeholders who collectively influence the final decision. In our...
Cost-Effectiveness Assessment of
Pharmaceuticals: Key Questions
Cost-effectiveness assessment is a crucial
element of the administrative process for determining drug reimbursement, not
only in the Czech Republic. A well-prepared cost-effectiveness analysis,
including budget impact assessment, not only supports the applicant's arguments
but also minimizes requests for additional documentation from the State
Institute for Drug Control (SÚKL/Institute) via cooperation requests, which
have become standard practice.
This article presents a selection of key
questions that applicants seeking drug reimbursement (where cost-effectiveness
assessment is required) should be able to answer within their submitted
evaluation.
Cost-effectiveness assessment is a crucial element of the administrative process for determining drug reimbursement, not only in the Czech Republic. A well-prepared cost-effectiveness analysis,...
